Intratumor RNA interference of cell cycle genes slows down tumor progression

Gene Therapy

Volumn 18, Issue 7, 2011, Pages 727-733

  Dharmapuri, S ^a,d   Peruzzi, D ^a,d   Marra, E ^a,f   Palombo, F ^a,g   Bett, A J ^b   Bartz, S R ^c   Yong, M ^c   Ciliberto, G ^a,h   La Monica, N ^a,i   Buser, C A ^b   Toniatti, C ^b,e   Aurisicchio, L ^a,f  

^a IRBM   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Sirna Therapeutics Inc   (United States)

^d 29 39 Brunswick Square   (United Kingdom)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Grande Ospedale Metropolitano   (Italy)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

ⁱ HYBRIDON INC   (United States)

Author keywords

KSP; liponanoparticle; PLK1; siRNA

Indexed keywords

ADENOVIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; KINESIN; LNP 201; LUCIFERASE; NANOPARTICLE; POLO LIKE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CANCER INHIBITION; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; GENE SILENCING; HELA CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; LIPOSOMAL GENE DELIVERY SYSTEM; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PHARYNX CARCINOMA; PRIORITY JOURNAL; REPORTER GENE; RNA INTERFERENCE; TONGUE CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CHOLESTEROL; DISEASE PROGRESSION; GENE SILENCING; GENE TARGETING; GENES, CDC; GENETIC VECTORS; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; POLYETHYLENE GLYCOLS; RNA INTERFERENCE; TRANSDUCTION, GENETIC;

ANIMALIA;

EID: 79960122358     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.27     Document Type: Article

References (37)

1. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33.
2. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738. (Pubitemid 33009951)
3. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418: 38-39. (Pubitemid 34742563)
4. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263-270. (Pubitemid 40460553)
5. Song XT, Evel-Kabler K, Rollins L, Huang XF, Chen SY. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 2006; 3: e11.
6. Peng S, Kim TW, Lee JH, Yang M, He L, Hung CF et al. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 2005; 16: 584-593. (Pubitemid 40740926)
7. Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005; 65: 309-316. (Pubitemid 40070823)
8. Wesche-Soldato DE, Chung CS, Lomas-Neira J, Doughty LA, Gregory SH, Ayala A. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 2005; 106: 2295-2301. (Pubitemid 41510799)
9. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004; 14: 1139-1143. (Pubitemid 38229843)
10. Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007; 117: 3615-3622. (Pubitemid 350224067)
11. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-1007. (Pubitemid 41114035)
12. Michiue H, Eguchi A, Scadeng M, Dowdy SF. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 2009; 8: 2306-2313.
13. Pathak A, Vyas SP, Gupta KC. Nano-vectors for efficient liver specific gene transfer. Int J Nanomedicine 2008; 3: 31-49. (Pubitemid 351517074)
14. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 2010; 267: 9-21.
15. de Fougerolles A, Novobrantseva T. siRNA and the lung: research tool or therapeutic drug? Curr Opin Pharmacol 2008; 8: 280-285.
16. Abrams MT, Koser ML, Seitzer J, Williams SC, DiPietro MA, Wang Wet al. Evaluation of efficacy, biodistribution and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 2010; 18: 171-180.
17. Wang QZ, Lv YH, Diao Y, Xu R. The design of vectors for RNAi delivery system. Curr Pharm Des 2008; 14: 1327-1340. (Pubitemid 351997826)
18. Ruiz R, Witting SR, Saxena R, Morral N. Robust hepatic gene silencing for functional studies using helper-dependent adenovirus vectors. Hum Gene Ther 2008; 20: 87-94.
19. Sakamoto N, Tanabe Y, Yokota T, Satoh K, Sekine-Osajima Y, Nakagawa M et al. Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. J Gastroenterol Hepatol 2008; 23: 1437-1447.
20. Zhu H, Zhu Y, Hu J, Hu W, Liao Y, Zhang J et al. Adenovirus-mediated small hairpin RNA targeting Bcl-XL as therapy for colon cancer. Int J Cancer 2007; 121: 1366-1372. (Pubitemid 47293807)
21. Dai Y, Qiao L, Chan KW, Yang M, Ye J, Zhang R et al. Adenovirus-mediated downregulation of X-linked inhibitor of apoptosis protein inhibits colon cancer. Mol Cancer Ther 2009; 8: 2762-2770.
22. Zheng JN, Pei DS, Mao LJ, Liu XY, Mei DD, Zhang BF et al. Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther 2009; 16: 20-32.
23. Zhang Y, Xu W. Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med Chem 2008; 8: 698-704.
24. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107-117. (Pubitemid 46160987)
25. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 2007; 10: 162-181. (Pubitemid 47449762)
26. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737-747.
27. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004; 32: e49.
28. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-178. (Pubitemid 39545841)
29. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA et al. Evidence of RNAi in humans from systematically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-1071.
30. Knight SD, Parrish CA. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP. Curr Top Med Chem 2008; 8: 888-904. (Pubitemid 351984711)
31. Rickert KW, Schaber M, Torrent M, Neilson LA, Tasber ES, Garbaccio R et al. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch Biochem Biophys 2008; 469: 220-231. (Pubitemid 350298109)
32. Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME et al. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n- [(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2- (hydroxymethyl)-N-methyl-2-phenyl-2, 5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. J Med Chem 2008; 51: 4239-4252. (Pubitemid 352032448)
33. Steegmaier M, Hoffmann M, Baum A, Léná rt P, Petronczki M, Krssák M et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-322. (Pubitemid 46241881)
34. Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 2007; 26: 5793-5807. (Pubitemid 47312808)
35. Appledorn DM, Patial S, McBride A, Godbehere S, Van Rooijen N, Parameswaran N et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 2008; 181: 2134-2144.
36. Dharmapuri S, Peruzzi D, Aurisicchio L. Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin Biol Ther 2009; 9: 1279-1287.
37. Renaut L, Bernard C, D'Halluin JC. A rapid and easy method for production and selection of recombinant adenovirus genomes. J Virol Methods 2002; 100: 121-131. (Pubitemid 34003631)